INTRODUCTION:

Post traumatic stress disorder (PTSD) is highly commorbid among individuals with opioid use disorder (OUD). PTSD among people with OUD is associated with severe opioid use, depression, and suicidality. Tanzania has seen a rise in opioid use over the past few years and the presence of PTSD among people with OUD predisposes patients to more negative impacts and impedes the recovery process. We aim to assess the prevalence and factors associated with PTSD among individuals with opioid use disorder (OUD) attending medication-assisted therapy (MAT) clinic in comparison to non-opioid...

CSUCH’s data visualisation tool can be used to estimate substance use trends across the country. The data helps inform programs, practices, and research to protect communities, save lives, and improve the well-being of people in Canada.

Spotlight: Top 3 causes of death due to substance use in Canada 

More than 200 people died each day due to substance use (SU) in 2020 (the latest year for which data are available). That works out to 73,994 deaths that year. The average age of death due to SU was 45 years. Tobacco use caused 63% (46,366) of SU-related deaths, followed by alcohol at 23%...

Background
A non-medicalized safer supply model called a “Compassion Club” has recently been evaluated. The model involved providing rigorously tested and accurately labeled illicit substances to members at cost. Operating for 14 months in Vancouver's Downtown Eastside, the initiative aimed to explore the effects and feasibility of this approach among individuals at risk of fatal overdose.

Methods
At the one-year mark, 43 club members completed a survey for this cross-sectional analysis. Descriptive statistics were used to assess the perceived impact of membership on factors like drug use...

Researchers at Virginia Commonwealth University (VCU) have developed a new version of a medication for opioid use disorder that could offer longer-lasting treatment. Current medications for opioid addiction often require daily doses, but the new formulation of nor-levo-alpha-acetylmethadol (nor-LAAM) is designed to be taken once a month or less frequently. This long-acting medication has shown promise in reducing opioid use and withdrawal symptoms in rodent models. The goal is to provide an alternative to existing treatments like methadone and buprenorphine, which come with barriers such as...